Xia Zang
Yancheng, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Long-term protection from naturally acquired immunity against hepatitis E virus reinfection.
Journal: Nature communications
Published: July 29, 2025
Effectiveness of a hepatitis E vaccine against medically-attended symptomatic infection in HBsAg-positive adults from a test-negative design study.
Journal: Nature communications
Published: September 01, 2024
Substantial spillover burden of rat hepatitis E virus in humans.
Journal: Nature communications
Published: July 22, 2024
A randomized phase I trial of intranasal SARS-CoV-2 vaccine dNS1-RBD in children aged 3-17 years.
Journal: NPJ vaccines
Published: July 09, 2024
Active surveillance of hepatitis E: a 10-year epidemiological analysis in a city in eastern China.
Journal: Emerging microbes & infections
Published: June 26, 2024
Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study.
Journal: Expert review of vaccines
Published: May 02, 2024
Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: July 21, 2023
Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial.
Journal: The Lancet regional health. Western Pacific
Published: February 06, 2023
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Journal: The Lancet. Respiratory medicine
Published: November 16, 2021
Showing 1-10 of 10
Last Updated: 09/26/2026